Table 2.

Neuroactive Steroid-based Drugs for the Treatment of Depression That Have Been Approved or are Currently Under Investigation.

Drug	Structure	Development phase	Indication
Brexanolone		FDA-approved in 2019 [211]	PPD
Zuranolone		Phase 3	PPD MDD
PRAX-114	Not available	Phase 2/3a	MDD
PH10		Phase 2a	MDD

^aThe phase 2/3 trial was completed and failed to meet its primary endpoint.

FDA US Food and Drug Administration, MDD major depressive disorder, PPD postpartum depression.